STM Journals Peer-reviewed research from Consortium e-Learning Network

Research and Reviews: A Journal of Pharmaceutical Science Review Article

Exploring Recent Advancements in Nanomedicine for Tumor Microenvironmental Tissue Engineering

  1. Sudhamani T Department of Pharmaceutics, Vivekanandha Pharmacy College for Women, Sankari
  2. Jananipriya K Department of Pharmaceutics, Vivekanandha Pharmacy College for Women, Sankari
  3. Dhanasekar J Department of Pharmaceutics, Vivekanandha Pharmacy College for Women, Sankari
  4. Selvakumar M Department of Pharmaceutics, Vivekanandha Pharmacy College for Women, Sankari
  5. Nandhakumaran S Department of Pharmaceutics, Vivekanandha Pharmacy College for Women, Sankari
  6. Lathamani L Department of Pharmaceutics, Vivekanandha Pharmacy College for Women, Sankari

Abstract

The combination of tissue engineering and nanomedicine is transforming cancer treatment by offering creative ways to get around problems with conventional therapies. Recent developments in nanomedicine are examined in this review, with an emphasis on how they might be used to comprehend and control the tumor microenvironment (TME), a dynamic and complex environment that has a major impact on the course of cancer and the effectiveness of treatment. Targeted interactions inside the TME are made possible by emerging nanotechnologies that provide regulated release mechanisms, real-time monitoring, and precise drug administration. At the same time, tissue engineering techniques have proved crucial in developing physiologically appropriate 3D tumor models that more closely resemble in vivo circumstances than conventional 2D cultures. Deeper understanding of tumor biology, angiogenesis, immunological evasion, and treatment resistance is made possible by these engineered models. Recent advancements in stimuli-responsive nanoparticles, organ-on-chip platforms, and biomaterials have improved the ability to study and modify the TME for therapeutic advantage. When taken as a whole, these multidisciplinary developments have enormous potential for creating more potent, patient-specific cancer treatments as well as enhancing drug screening and disease modeling systems. This study emphasizes how tissue engineering and nanomedicine work together to revolutionize personalized medicine and cancer research.

Keywords

References (92)

  1. Lee S, Kim G, Lee J, Lee AC, Kwon S. Mapping cancer biology in space: applications and perspectives on spatial omics for oncology. Molecular Cancer. 2024;23(1). doi:10.1186/s12943-024-01941-z
  2. Ungefroren H, Sebens S, Seidl D, Lehnert H, Hass R. Interaction of tumor cells with the microenvironment. Cell Communication and Signaling. 2011;9(1):18. doi:10.1186/1478-811x-9-18
  3. Ma H, Xu H, Qin J. Biomimetic tumor microenvironment on a microfluidic platform. Biomicrofluidics. 2013;7(1). doi:10.1063/1.4774070
  4. Dzobo K. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic. OMICS: A Journal of Integrative Biology. 2020;24(4):175-179. doi:10.1089/omi.2020.0019
  5. Guller AE, Grebenyuk PN, Shekhter AB, Zvyagin AV, Deyev SM. Bioreactor-Based Tumor Tissue Engineering. Acta Naturae. 2016;8(3):44-58. doi:10.32607/20758251-2016-8-3-44-58
  6. Son B, Lee S, Youn H, Kim E, Kim W, Youn B. The role of tumor microenvironment in therapeutic resistance. Oncotarget. 2016;8(3):3933-3945. doi:10.18632/oncotarget.13907
  7. Zhang Q, Lou Y, Fang H, Sun S, Jin R, Ji Y, et al. Cancer‑associated fibroblasts under therapy‑induced senescence in the tumor microenvironment (Review). Experimental and Therapeutic Medicine. 2024;27(4). doi:10.3892/etm.2024.12438
  8. Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Letters. 2017;387:61-68. doi:10.1016/j.canlet.2016.01.043
  9. Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. Journal of Biomedical Science. 2018;25(1). doi:10.1186/s12929-018-0426-4
  10. Xu J, Lamouille S, Derynck R. TGF-β-induced epithelial to mesenchymal transition. Cell Research. 2009;19(2):156-172. doi:10.1038/cr.2009.5
  11. Dai X, Guo X, Liu J, Cheng A, Peng X, Jia R, et al. Circular RNA circGRAMD1B inhibits gastric cancer progression by sponging miR-130a-3p and regulating PTEN and p21 expression. Aging. 2019;11(23):9689–708. doi:10.18632/aging.102415.
  12. Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nature Reviews Drug Discovery. 2018;18(2):99-115. doi:10.1038/s41573-018-0004-1
  13. Ramamonjisoa N, Ackerstaff E. Characterization of the Tumor Microenvironment and Tumor–Stroma Interaction by Non-invasive Preclinical Imaging. Frontiers in Oncology. 2017;7. doi:10.3389/fonc.2017.00003
  14. Maishi N, Hida K. Tumor endothelial cells accelerate tumor metastasis. Cancer Science. 2017;108(10):1921-1926. doi:10.1111/cas.13336
  15. Watanabe K, Panchy N, Noguchi S, Suzuki H, Hong T. Combinatorial perturbation analysis reveals divergent regulations of mesenchymal genes during epithelial-to-mesenchymal transition. NPJ Syst Biol Appl. 2019;5(1). doi:10.1038/s41540-019-0091-9.
  16. Li H, Courtois ET, Sengupta D, Tan Y, Chen KH, Goh JJL, et al. Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors. Nature Genetics. 2017;49(5):708-718. doi:10.1038/ng.3818
  17. Lee SY, Jeong EK, Jeon HM, Kim CH. Implications of epithelial-mesenchymal transition in cancer stem cells: therapeutic targets and clinical relevance. Expert Rev Mol Sci. 2014;16(3):289–300. doi:10.1586/14737175.2014.884927.
  18. Talukdar S, Bhoopathi P, Emdad L, Das S, Sarkar D, Fisher PB. Dormancy and cancer stem cells: an enigma for cancer therapeutic targeting. Adv Cancer Res. 2019;141:43–84. doi:10.1016/bs.acr.2018.11.002.
  19. Butti R, Gunasekaran VP, Kumar TVS, Banerjee P, Kundu GC. Breast cancer stem cells: Biology and therapeutic implications. The International Journal of Biochemistry & Cell Biology. 2019;107:38-52. doi:10.1016/j.biocel.2018.12.001
  20. Batlle E, Clevers H. Cancer stem cells revisited. Nature Medicine. 2017;23(10):1124-1134. doi:10.1038/nm.4409
  21. Kreso A, Dick JE. Evolution of the Cancer Stem Cell Model. Cell Stem Cell. 2014;14(3):275-291. doi:10.1016/j.stem.2014.02.006
  22. Najafi M, Mortezaee K, Majidpoor J. Cancer stem cell (CSC) resistance drivers. Life Sciences. 2019;234:116781. doi:10.1016/j.lfs.2019.116781
  23. Fontana F, Carollo E, Melling GE, Carter DRF. Extracellular Vesicles: Emerging Modulators of Cancer Drug Resistance. Cancers. 2021;13(4):749. doi:10.3390/cancers13040749
  24. Vasconcelos MH, Caires HR, Ābols A, Xavier CPR, Linē A. Extracellular vesicles as a novel source of biomarkers in liquid biopsies for monitoring cancer progression and drug resistance. Drug Resistance Updates. 2019;47:100647. doi:10.1016/j.drup.2019.100647
  25. Camorani S, Hill BS, Fontanella R, Greco A, Gramanzini M, Auletta L, et al. Inhibition of bone marrow-derived mesenchymal stem cells homing towards triple-negative breast cancer microenvironment using an anti-PDGFRβ aptamer. Theranostics. 2017;7(15):3595–607. doi:10.7150/thno.20481.
  26. Nandy SB, Arumugam A, Subramani R, Pedroza D, Hernandez K, Saltzstein E, et al. MicroRNA-125a influences breast cancer stem cells by targeting leukemia inhibitory factor receptor which regulates the Hippo signaling pathway. Oncotarget. 2015;6(19):17366–78. doi:10.18632/oncotarget.4020.
  27. O’Conor CJ, Chen T, González I, Cao D, Peng Y. Cancer Stem Cells in Triple-Negative Breast Cancer: a Potential Target and Prognostic Marker. Biomarkers in Medicine. 2018;12(7):813-820. doi:10.2217/bmm-2017-0398
  28. McDermott SP, Wicha MS. Targeting breast cancer stem cells. Molecular Oncology. 2010;4(5):404-419. doi:10.1016/j.molonc.2010.06.005
  29. Azzam DJ, Zhao D, Sun J, Minn AJ, Ranganathan P, Drews‐Elger K, et al. Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ‐secretase inhibitor drug responses. EMBO Molecular Medicine. 2013;5(10):1502-1522. doi:10.1002/emmm.201302558
  30. Lindner U, Kramer J, Behrends J, Driller B, Wendler NO, Boehrnsen F, et al. Improved proliferation and differentiation capacity of human mesenchymal stromal cells cultured with basement-membrane extracellular matrix proteins. Cytotherapy. 2010;12(8):992–1005. doi:10.3109/14653249.2010.501791.
  31. Keller PJ, Arendt LM, Skibinski A, Logvinenko T, Klebba I, Dong S, et al. Defining the cellular precursors to human breast cancer. Proceedings of the National Academy of Sciences. 2011;109(8):2772-2777. doi:10.1073/pnas.1017626108
  32. Ye J, Wu D, Wu P, Chen Z, Huang J. The cancer stem cell niche: cross talk between cancer stem cells and their microenvironment. Tumor Biology. 2014;35(5):3945-3951. doi:10.1007/s13277-013-1561-x
  33. Bussard KM, Mutkus L, Stumpf K, Gomez-Manzano C, Marini FC. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Research. 2016;18(1). doi:10.1186/s13058-016-0740-2
  34. Su S, Chen J, Yao H, Liu J, Yu S, Lao L, et al. CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness. Cell. 2018;172(4):841-856.e16. doi:10.1016/j.cell.2018.01.009
  35. Koliaraki V, Pallangyo CK, Greten FR, Kollias G. Mesenchymal Cells in Colon Cancer. Gastroenterology. 2017;152(5):964-979. doi:10.1053/j.gastro.2016.11.049
  36. Tao L, Huang G, Song H, Chen Y, Chen L. Cancer associated fibroblasts: An essential role in the tumor microenvironment. Oncology Letters. 2017;14(3):2611-2620. doi:10.3892/ol.2017.6497
  37. Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes & Development. 2016;30(9):1002-1019. doi:10.1101/gad.279737.116
  38. Wang X, Sun W, Shen W, Xia M, Chen C, Xiang D, et al. Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis. Journal of Hepatology. 2016;64(6):1283-1294. doi:10.1016/j.jhep.2016.01.019
  39. Quante M, Tu SP, Tomita H, Gonda T, Wang SSW, Takashi S, et al. Bone Marrow-Derived Myofibroblasts Contribute to the Mesenchymal Stem Cell Niche and Promote Tumor Growth. Cancer Cell. 2011;19(2):257-272. doi:10.1016/j.ccr.2011.01.020
  40. Kalluri R. The biology and function of fibroblasts in cancer. Nature Reviews Cancer. 2016;16(9):582-598. doi:10.1038/nrc.2016.73
  41. Wang Z, Xu Q, Zhang N, Du X, Xu G, Yan X, et al. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. Cancer Res. 2022;82(6):1630–44. doi:10.1158/0008-5472.CAN-21-1305.
  42. Malfitano AM, Pisanti S, Napolitano F, Di Somma S, Martinelli R, Portella G. Tumor-Associated Macrophage Status in Cancer Treatment. Cancers. 2020;12(7):1987. doi:10.3390/cancers12071987
  43. Pan Y, Yu Y, Wang X, Zhang T. Tumor-Associated Macrophages in Tumor Immunity. Frontiers in Immunology. 2020;11. doi:10.3389/fimmu.2020.583084
  44. Komohara Y, Fujiwara Y, Ohnishi K, Takeya M. Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy. Advanced Drug Delivery Reviews. 2016;99:180-185. doi:10.1016/j.addr.2015.11.009
  45. Noy R, Pollard JW. Tumor-Associated Macrophages: From Mechanisms to Therapy. Immunity. 2014;41(1):49-61. doi:10.1016/j.immuni.2014.06.010
  46. Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Frontiers in Physiology. 2014;5. doi:10.3389/fphys.2014.00075
  47. Mantovani A, Allavena P. The interaction of anticancer therapies with tumor-associated macrophages. Journal of Experimental Medicine. 2015;212(4):435-445. doi:10.1084/jem.20150295
  48. Genin M, Clement F, Fattaccioli A, Raes M, Michiels C. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer. 2015;15(1). doi:10.1186/s12885-015-1546-9
  49. Pathria P, Louis TL, Varner JA. Targeting Tumor-Associated Macrophages in Cancer. Trends in Immunology. 2019;40(4):310-327. doi:10.1016/j.it.2019.02.003
  50. Chanmee T, Ontong P, Konno K, Itano N. Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment. Cancers. 2014;6(3):1670-1690. doi:10.3390/cancers6031670
  51. He Z, Ding J, Huie M, Yang Y, Zhang Y. Role of tumor-associated macrophages in the development of gastrointestinal tumors. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188616. doi:10.1016/j.bbcan.2021.188616.
  52. Jang J, Kim J, Lee K, Kim C. Tumor-associated macrophage as a prognostic biomarker of non-small cell lung cancer: a meta-analysis. Sci Rep. 2020;10(1):15203. doi:10.1038/s41598-020-72181-w.
  53. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nature Reviews Cancer. 2008;8(8):618-631. doi:10.1038/nrc2444
  54. Lin EY, Pollard JW. Tumor-Associated Macrophages Press the Angiogenic Switch in Breast Cancer. Cancer Research. 2007;67(11):5064-5066. doi:10.1158/0008-5472.can-07-0912
  55. Hussain M, Adah D, Tariq M, Lu Y, Zhang J, Liu J. CXCL13/CXCR5 signaling axis in cancer. Life Sciences. 2019;227:175-186. doi:10.1016/j.lfs.2019.04.053
  56. Wang L, Zhu B, Zhang M, Wang X. Roles of CCL3 in tumor microenvironment. Cancer Manag Res. 2020;12:6163–72. doi:10.2147/CMAR.S258237.
  57. Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes & Development. 2011;25(23):2465-2479. doi:10.1101/gad.180331.111
  58. Bonapace L, Coissieux MM, Wyckoff J, Mertz KD, Varga Z, Junt T, et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature. 2014;515(7525):130-133. doi:10.1038/nature13862
  59. Qiu SQ, Waaijer SJH, Zwager MC, de Vries EGE, van der Vegt B, Schröder CP. Tumor-associated macrophages in breast cancer: Innocent bystander or important player? Cancer Treatment Reviews. 2018;70:178-189. doi:10.1016/j.ctrv.2018.08.010
  60. Ruffell B, Coussens LM. Macrophages and Therapeutic Resistance in Cancer. Cancer Cell. 2015;27(4):462-472. doi:10.1016/j.ccell.2015.02.015
  61. Goswami KK, Ghosh T, Ghosh S, Sarkar M, Bose A, Baral R. Tumor promoting role of anti-tumor macrophages in tumor microenvironment. Cellular Immunology. 2017;316:1-10. doi:10.1016/j.cellimm.2017.04.005
  62. Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nature Reviews Drug Discovery. 2018;17(12):887-904. doi:10.1038/nrd.2018.169
  63. Zhou J, Tang Z, Gao S, Li C, Feng Y, Zhou X. Tumor-Associated Macrophages: Recent Insights and Therapies. Frontiers in Oncology. 2020;10. doi:10.3389/fonc.2020.00188
  64. Ovais M, Guo M, Chen C. Tailoring Nanomaterials for Targeting Tumor‐Associated Macrophages. Advanced Materials. 2019;31(19). doi:10.1002/adma.201808303
  65. Ramesh A, Brouillard A, Kumar S, Nandi D, Kulkarni A. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy. Biomaterials. 2020;227:119559. doi:10.1016/j.biomaterials.2019.119559
  66. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nature Reviews Clinical Oncology. 2017;14(7):399-416. doi:10.1038/nrclinonc.2016.217
  67. Macrophages. International Review of Cell and Molecular Biology. 2019:73-93. doi:10.1016/bs.ircmb.2018.07.001
  68. Xu J, Escamilla J, Mok S, David J, Priceman S, West B, et al. CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer. Cancer Research. 2013;73(9):2782-2794. doi:10.1158/0008-5472.can-12-3981
  69. Strachan DC, Ruffell B, Oei Y, Bissell MJ, Coussens LM, Pryer N, et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+T cells. OncoImmunology. 2013;2(12):e26968. doi:10.4161/onci.26968
  70. Holmgaard RB, Zamarin D, Lesokhin A, Merghoub T, Wolchok JD. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine. 2016;6:50-58. doi:10.1016/j.ebiom.2016.02.024
  71. Papadopoulos KP, Gluck L, Martin LP, Olszanski AJ, Tolcher AW, Ngarmchamnanrith G, et al. First-in-human study of AMG 820, a monoclonal anti-colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumors. Clin Cancer Res. 2017;23(19):5703–10. doi:10.1158/1078-0432.CCR-16-3223.
  72. von Tresckow B, Morschhauser F, Ribrag V, Topp MS, Chien C, Seetharam S, et al. An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Clinical Cancer Research. 2015;21(8):1843-1850. doi:10.1158/1078-0432.ccr-14-1845
  73. Gomez-Roca CA, Italiano A, Le Tourneau C, Cassier PA, Toulmonde M, D’Angelo SP, et al. Phase I study of emactuzumab single agent in patients with locally advanced or metastatic solid tumors. Clin Cancer Res. 2019;25(17):5468–77. doi:10.1158/1078-0432.CCR-18-4123.
  74. Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. The Lancet Oncology. 2015;16(8):949-956. doi:10.1016/s1470-2045(15)00132-1
  75. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy. Cancer Cell. 2014;25(6):846-859. doi:10.1016/j.ccr.2014.05.016
  76. Kumar V, Donthireddy L, Marvel D, Condamine T, Wang F, Lavilla-Alonso S, et al. Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. Cancer Cell. 2017;32(5):654-668.e5. doi:10.1016/j.ccell.2017.10.005
  77. Dammeijer F, van Gulijk M, Mulder EE, Lukkes M, Klaase L, van den Bosch T, et al. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. Cancer Cell. 2020;38(5):685-700.e8. doi:10.1016/j.ccell.2020.09.001
  78. Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C, et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment. Proceedings of the National Academy of Sciences. 2018;115(17). doi:10.1073/pnas.1720948115
  79. Pathria P, Louis TL, Varner JA. Targeting Tumor-Associated Macrophages in Cancer. Trends in Immunology. 2019;40(4):310-327. doi:10.1016/j.it.2019.02.003
  80. Li C, Xu X, Wei S, Jiang P, Xue L, Wang J. Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer. Journal for ImmunoTherapy of Cancer. 2021;9(1):e001341. doi:10.1136/jitc-2020-001341
  81. Jeong H, Kim S, Hong BJ, Lee CJ, Kim YE, Bok S, et al. Tumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis. Cancer Research. 2019;79(4):795-806. doi:10.1158/0008-5472.can-18-2545
  82. Zhang Y, Cheng S, Zhang M, Zhen L, Pang D, Zhang Q, et al. High-Infiltration of Tumor-Associated Macrophages Predicts Unfavorable Clinical Outcome for Node-Negative Breast Cancer. PLoS ONE. 2013;8(9):e76147. doi:10.1371/journal.pone.0076147
  83. Goossens P, Rodriguez-Vita J, Etzerodt A, Masse M, Rastoin O, Gouirand V, et al. Membrane Cholesterol Efflux Drives Tumor-Associated Macrophage Reprogramming and Tumor Progression. Cell Metabolism. 2019;29(6):1376-1389.e4. doi:10.1016/j.cmet.2019.02.016
  84. Zhang J, Xu J, Zhang R, Sen A, Sun X, Chen J, et al. Pyruvate dehydrogenase kinase-mediated glycolytic metabolism promotes PD-L1 expression in tumor-associated macrophages. Front Immunol. 2022;13: 865940. doi:10.3389/fimmu.2022.865940.
  85. Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513(7519):559-563. doi:10.1038/nature13490
  86. Mu X, Shi W, Xu Y, Xu C, Zhao T, Geng B, et al. Tumor-derived lactate induces M2 macrophage polarization via the activation of the ERK/STAT3 signaling pathway in breast cancer. Cell Cycle. 2018;17(4):428-438. doi:10.1080/15384101.2018.1444305
  87. Penny HL, Sieow JL, Adriani G, Yeap WH, See Chi Ee P, San Luis B, et al. Warburg metabolism in tumor-conditioned macrophages promotes metastasis in human pancreatic ductal adenocarcinoma. OncoImmunology. 2016;5(8):e1191731. doi:10.1080/2162402x.2016.1191731
  88. Zhao D, Pan C, Sun J, Gilbert C, Drews-Elger K, Azzam DJ, et al. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene. 2014;34(24):3107-3119. doi:10.1038/onc.2014.257
  89. Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and Metabolism in the Tumor Microenvironment. Cell Metabolism. 2019;30(1):36-50. doi:10.1016/j.cmet.2019.06.001
  90. Singh Y, Pawar VK, Meher JG, Raval K, Kumar A, Shrivastava R, et al. Targeting tumor associated macrophages (TAMs) via nanocarriers. Journal of Controlled Release. 2017;254:92-106. doi:10.1016/j.jconrel.2017.03.395
  91. Poh AR, Ernst M. Targeting Macrophages in Cancer: From Bench to Bedside. Frontiers in Oncology. 2018;8. doi:10.3389/fonc.2018.00049
  92. Genard G, Lucas S, Michiels C. Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies. Frontiers in Immunology. 2017;8. doi:10.3389/fimmu.2017.00828
Support